Esbriet is an oral medication with anti fibrotic, anti-inflammatory, and antioxidant effects, mainly used to treat idiopathic pulmonary fibrosis (IPF) and delay disease progression through multiple pathways.

Core therapeutic efficacy

(1) Anti fibrotic effect: Inhibits the synthesis of pro fibrotic cytokines such as transforming growth factor - β (TGF - β) and reduces collagen deposition.

(2) Anti inflammatory effect: Downregulate inflammatory mediators such as tumor necrosis factor - α (TNF - α) and alleviate alveolar inflammatory response.

(3) Antioxidant effect: Clearing oxygen free radicals and reducing oxidative stress damage to lung tissue.

2 Clinical characteristics of action

(1) Disease modification: significantly reduces the annual decline rate of lung function (FVC) in IPF patients by 47%.

(2) Survival benefits: Extend progression free survival and reduce the risk of acute exacerbation.

(3) Quality of life: Improve patients' exercise tolerance and respiratory distress symptoms.

3. Details of the mechanism of action

(1) Molecular level: Regulating fibroblast proliferation and myofibroblast differentiation, blocking fibrosis signaling pathways.

(2) At the cellular level, it inhibits the synthesis of fibronectin and hyaluronic acid, reducing extracellular matrix deposition.

(3) Organizational level: Protect alveolar epithelial cells and delay lung tissue structural remodeling.